ABT-255 is a novel 2-pyridone antimicrobial agent for the treatment of tuberculosis. Both drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis showed efficacy in vitro and in vivo.
Iromycin A is a bacterial pyridone metabolite that inhibits nitric oxide synthase (NOS) activity, with selectivity for NOS III (endothelial NOS) over NOS I (neuronal NOS). Iromycin metabolites and derivatives block NADH oxidation in beef heart submitochondrial particles (IC50 = 0.461 μM for iromycin A).